BCIQ Profiles

Company Profile Report
0419 Adagio
BioCentury & Getty Images

Finance

Adagio raises $336M on promise of best-in-class COVID-19 mAb

Where Adagio sees a substantial market opportunity for its COVID-19 mAb

Adagio sees a substantial market opportunity for its COVID-19 mAb against new variants, in acute treatment settings and in individuals unwilling or unable to get vaccinated. 

Apr 20, 2021 | 1:29 AM GMT

Adagio’s strategy of prioritizing breadth of coverage over speed to market for its COVID-19 mAb discovery program appears to be paying off. Despite the ramping up of vaccinations worldwide, the biotech still sees a substantial market opportunity against new variants, in acute treatment settings and in people either unwilling or unable to take a vaccine.

Investors are buying into the story. On Monday, Adagio Therapeutics Inc.

Read the full 1194 word article

How to gain access

Continue reading with a
two-week free trial.